Arvinas (ARVN)
(Delayed Data from NSDQ)
$35.22 USD
+0.50 (1.44%)
Updated Apr 22, 2024 11:55 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 1 - 20 ( 198 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
AACR 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Enters the Neurodegeneration Space With LRRK2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Busy Year of Execution Across Pipeline, LRRK2 Enters Clinic
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Count Us In; ARVN Broadens CDK4/6i Combo Development
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
SABC Data Confirms the Strength of Vepdeg Palbo Combination Despite Palbo Dose Reductions
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Palbo Combo Continues to Impress; Increasing PT to $33/sh
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Palbo Combo Shows Impressive Efficacy; Bodes Well for VERITAC-3
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ARVN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Degrader Data Supports Pipeline Reprioritization Concerning ARV-766; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Bevdeg Makes Way for ARV-766; Upgrading to OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARV-471 Palbociclib Combination Might Be Superior To SOC-Our Thoughts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Ph 3 VERITAC-2 and 3 Trials Officially Underway
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R